Huijing Wu
Wuhan, 430079, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Glofitamab vs. real-world regimens in Chinese patients with third- or later-line relapsed/refractory diffuse large B-cell lymphoma: an external control study.
Journal: Cancer biology & medicine
Published: September 30, 2025
Phase 2 multicenter maintenance study of golidocitinib, A JAK1 selective inhibitor, in patients with peripheral T cell lymphomas after first-line systemic therapy (JACKPOT26).
Journal: Blood cancer journal
Published: August 21, 2025
Efficacy and safety of tazemetostat, an EZH2 inhibitor, in Chinese patients with relapsed/refractory follicular lymphoma: a multicentre, single-arm, phase 2 study.
Journal: EClinicalMedicine
Published: March 29, 2025
Skimmed milk intake reduces the risk of ER- breast cancer: a Mendelian randomization analysis.
Journal: Discover oncology
Published: July 16, 2024
Prolonged Complete Remission Using Tislelizumab for Hepatocellular Carcinoma After Adjuvant Chemotherapy Failure: A Case Report.
Journal: Journal of hepatocellular carcinoma
Published: March 05, 2024
Genomic features reveal potential benefit of adding anti-PD-1 immunotherapy to treat non-upper aerodigestive tract natural killer/T-cell lymphoma.
Journal: Leukemia
Published: November 22, 2023
Sintilimab (anti-PD-1 antibody) plus chidamide (histone deacetylase inhibitor) in relapsed or refractory extranodal natural killer T-cell lymphoma (SCENT): a phase Ib/II study.
Journal: Signal transduction and targeted therapy
Published: August 26, 2023
Involvement of spleen is associated with shorter survival in patients with angioimmunoblastic T cell lymphoma.
Journal: Journal of cancer research and clinical oncology
Published: May 14, 2023
Clinical and prognostic role of sarcopenia based on masticatory muscle index on MR images in patients with extranodal natural killer/T cell lymphoma, nasal type.
Journal: Annals of hematology
Published: April 27, 2023
Chinese expert consensus on the management of patients with hematologic malignancies infected with SARS-CoV-2.
Journal: Journal of cancer research and therapeutics
Published: April 06, 2023
The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 25, 2022
Last Updated: 09/26/2026